Editorial
Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome Ten years after the emergence of the antiphospholipid syndrome (APS) among connective/vascular disorders, its management remains largely empirical and sometimes controversial.
Prevention of recurrent thrombosis is obviously a main concern for clinicians dealing with APS. Indeed, reported recurrence rates are high. Among 38 patients with primary APS and deep vein thrombosis reported by Asherson et aI. 1, multiple or bilateral venous involvement was present in 13 (34%) and pulmonary embolism occurred in 18 (47%). Ten of these 38 (26%) also had arterial events 1. In the large cohort of systemic lupus erythematosus (SLE) patients studied by Alarcon-Segovia et al., the statistical association between venous thrombosis and the presence of anticardiolipin antibodies (aCL) was reinforced in those with recurrences. . High rates of recurrent thrombosis and/or pulmonary embolism were also reported in other series 3-5 as they were with some of the therapeutic regimens studied in papers that are detailed later. In this respect, APS offers some similarities with Beh~et's syndrome where venous and/or arterial involvement is frequently multiple but the prevalence of pulmonary embolism is much higher in APS~.
Until recently, data concerning the prevention of recurrent thrombosis in APS were scarce and did not allow for any clear conclusion. Three recently published papers and two others reported in this issue of Lupus add important information. All have compared recurrence rates observed under different regimens.
Rosove et c~1.7 retrospectively studied 70 APS patients with a prior history of venous (39 patients) or arterial (31 1 patients) thrombosis for a mean follow-up of 5 years. Fourteen patients had SLE and the others had primary APS with chronic thrombocytopenia as the main feature in five. Thirty-seven (53%) patients had 54 recurrent events. Recurrence rates durin~ 'no treatment', aspirin, low (international normalized ration (INR) z 1.9), intermediate (INR 2-2.9) and high (INR to-3.0) warfarin therapy were 0.19, 0.32, 0.57, 0.07 and 0.00 per patient year, respectively. The INRs coincident with thrombosis ranged from 1.42 to 2.6 in warfarin-treated patients. These results significantly favoured the use of high-dose warfarin.
Derksen et all 8 retrospectively studied 19 patients with antiphospholipid antibodies (aPL) and a history of venous thromboembolic episodes only for a median follow-up of 93 months. All but one had SLE or lupus-like disease. The follow-up period was divided into periods with and without oral anticoagulants. Aspirin was not studied. Twelve patients (63%) experienced further venous thromboembolic episodes. Using the Kaplan-Meier method, the 8 years probability of venous recurrence-free survival was 100% with anticoagulants (aimed at an INR between 2.5 and 4.0).
After anticoagulant withdrawal, the probability of venous recurrence rose to 50% and 78% at 2 and 8 years, respectively8. The difference was strikingly significant.
However, two patients had myocardial infarction during adequate treatment with anticoagulants. Vlachoyiannopoulos et aI.9 report in this issue of Lupus 30 APS patients with a history of thrombosis affecting veins (18 patients) or arteries ( I patients) in all but one. APS was primary in 21 patients. The mean follow-up after the first thrombotic event was 3.4 years. Recurrence rates on aspirin (100 mg daily) plus low-dose (10-15 mg daily) prednisone, warfarin (INR between 2 and 2.6), immunosuppressive therapy (~.5-1 mg/kg/day prednisone alone or associated with azathioprine or cyclophosphamide pulses without antithrombotic therapy) or no therapy at all were 0.13, 0.2, 0.7 and 0.88, respectively. Compared with no treatment, on the one hand aspirin plus prednisone and on the other warfarin were significantly associated with a longer thrombosis-free survival whereas immunosuppressive therapy was not.
Rivier et al.,&dquo; from the London group, report data on 23 patients, half with prior venous and half with arterial thrombosis. Ten had primary APS, seven lupus-like disease and six SLE. Treatments compared were (1) aspirin alone (75 mg daily), (2) low/medium-dose warfarin (INR between 2.0 and 2.9) zaspirin, and (3) high-dose warfarin (INR > 2.9) ± aspirin. Many patients had received two or three of these regimens. Mean follow-up was 18 months for patients receiving warfarin. By one-tail Fisher's test, treatment 3 was significantly more effective than treatment 1 in preventing further thrombotic events but there was just a trend in favour of treatment 3 compared with treatment 2 and of treatment 2 compared with treatment 1. The highest INR coincident with thrombosis was 2.7. It should be noted that this study compared percentages of patients who had recurrences irrespective of follow-up duration and not the recurrence rates per year. The only study devoted to initial arterial events (cerebral or ocular infarction/transient ischaemic attack (TIA)) has been reported by the APASS group&dquo;. Among 75 patients prospectively studied, 10 had ARA-definite SLE and 32 had abnormal ANA. Some patients had echocardiographic abnormalities but no vegetations or thrombi were identified. The mean follow-up was 1.14 years. Recurrent stroke or TIA was experienced by 26 patients (35%) and was negatively associated with the empirical use of dipyridamole plus aspirin (odds ratio 0.25, 95% CI 0.07-0.88) but not with those of warfarin. Data on venous events were not provided.
Although limited in scope, these studies are nevertheless a great step forward. The criticisms are obvious: except for Levine's study, all are retrospective and none is controlled. Some patients did not receive all of the compared regimens.
Patients varied from one study to another with regard to the site of initial thrombosis and to their precise diagnosis, i.e. SLE or primary APS. Associated drugs such as hydroxychloroquine, whose antithrombotic properties have recently been demonstrated, were rarely mentioned. When comparing aspirin with warfarin in SLE, hydroxychloroquine treatment could introduce some bias favouring warfarin, if one considers that it probably adds its antiplatelet properties to the anticoagulant action of warfarin whereas it could be redundant with aspirin. It should also be noticed that the favourable results obtained with warfarin in Rosove's study 7 included some patients who actually received warfarin plus aspirin. All these studies compared the recurrence rates observed with different regimens administered during different periods of time. A prerequisite for such comparisons supposes that the risks of thrombosis are identical whatever the period considered. The surprising 0.53 annual recurrence rate observed with heparin therapy compared with 0.19 with 'no treatment' suggests that this was probably not the case in Rosove's study7. One can suppose that physicians tended to give heparin when the risk was considered high (for example during pregnancy) and 'no treatment' when it was low, which could explain such surprising results. The validity of the inclusion of pregnancy or immediate post-partum periods in that study and others is debatable7,8,1O. Oral anticoagulants cannot be used during these periods where the risk of thrombosis is obviously high and this results in an artificial lowering of the recurrence rates observed under warfarin.
In spite of their limits, it can be concluded from these studies that when used at doses providing an INR of >3, warfarin procures a very significant protection. Unfortunately, its long-term administration implies risks. Major bleeding occurred in three (two subdural hematomas and a pulmonary haemorrhage) of 55 patients in ,Rosove's stud y7, in two (one intra-abdominal bleeding and one profound anaemia) of 19 in Derksen's study8, and in four of 23 in Rivier'slo. These proportions are all the more alarming as the duration of follow-up was relatively short. It could be argued that bleeding episodes occurred when INR was too high but such problems seem to be unavoidable despite careful monitoring. Long-term 'zero-default' warfarin treatment frequently remains a dream because of variable compliance, fluctuating warfarin requirement4 and associated drugs that can modify anticoagulant potency, especially in patients with SLE. On the other hand, severe aspirin-induced bleeding is uncommon7. But does aspirin procure any benefit? The negative answer provided by Rosove's study is by no means a definitive conclusion. It has to be weighed against the significant reduction of recurrent stroke/TIA reported by the APASS group with the use of aspirin plus dipyridamolell and with the Greek study showing that warfarin (INR 2 to 2.6) or aspirin plus low-dose prednisone were equally effective.
Finally, both benefits and risks are probably much higher with high-dose warfarin than with aspirin. The choice between these treatments is frequently critical for clinicians when they consider the benefIt/risk ratio.
